
MED-EL announces that it has received FDA approval for the SYNCHRONY EAS (Electric Acoustic Stimulation). EAS uses both cochlear implant technology, and hearing aid technology, to provide a solution for those with stable low-frequency hearing loss.

MED-EL announces that it has received FDA approval for the SYNCHRONY EAS (Electric Acoustic Stimulation). EAS uses both cochlear implant technology, and hearing aid technology, to provide a solution for those with stable low-frequency hearing loss.
— The World’s Newest, Most Advanced Electro Acoustic Stimulation (EAS) System Receives Regulatory Approval for Commercial Release in Europe —
VALENCIA, Calif., May 28, 2015 – Advanced Bionics (AB), a global leader in cochlear implant technology and a company of the Sonova Group, announced today that the new Naída CI Q90 EAS received TÜV approval for distribution in Europe. With the arrival of this new product, now more than ever, cochlear implant recipients have access to the combined technologies of AB and Phonak, the innovation leaders in cochlear implants and hearing instruments.
The Naída CI Q90 EAS offers a truly integrated electro acoustic hearing solution in addition to many of the popular features delivered with the Naída CI platform:
Cochlear announced that the FDA advisory panel has voted favorably on a hybrid cochlear implant system. Hybrid cochlear implants combine the functionality of a cochlear implant with that of a hearing aid. The hearing aid portion provides additional low-frequency information. These systems are currently available from both Cochlear and MED-EL in some markets outside of the US.